Article Text

AB0074 Interleukin-23 in Serum of Patients with Antineutrophil Cytoplasmic Antibody- Associated Systemic Vasculitis
  1. T.V. Beketova,
  2. E.N. Aleksandrova,
  3. N.O. Nikonorova,
  4. E.L. Nasonov
  1. V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation


Background There is probably a systemic shift of cytokine production in patients with antineutrophil cytoplasmic antibody (ANCA)- associated systemic vasculitis (AAV) toward the Th17 cytokine response. We investigated whether interleukin-23 (IL-23), Th17- related cytokine, have any correlations with disease activity, clinical manifestations and treatment in AAV.

Objectives To analyse the concentration of interleukin-23 (IL-23) in serum of AAV patients, compared with healthy controls (HC).

Methods An enzyme- linked immunosorbent assay (ELISA) was used to analyse the serum concentration of IL-23 in 40 patients with AAV (median age 44 yrs (20- 65); F:M=1,11) and 8 HC (median age 47 yrs (21- 66); F:M=1,67). 23 patients were classified as granulomatosis with polyangiitis (GPA), 14- microscopic polyangiitis (MPA), and 3- eosinophilic granulomatosis with polyangiitis (EGPA). 26 patients were examined in active phase, 28- in remission (in 22/28 remission was induced by rituximab). The correlations between the levels of IL-23 and disease activity, clinical parameters were analysed.

Results The levels of IL-23 increased significantly in the serum of active PR3-ANCA patients before treatment compared with HC (median 41.9 pg/ ml and 13.1 pg/ ml, respectively, p<0,05). As immunosuppressive and anti B cell therapy (rituximab) in AAV patients resulted in effective suppression of serum IL-23 (5,2- 8,8 pg/ ml).

Table 1.

Characteristics of patients and controls

Conclusions There is a prospect further study of IL-23 and functionally similar cytokines in the pathogenesis of AAV.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.